| dc.creator | De Nunzio C., Brucker B., Bschleipfer T., Cornu J.-N., Drake M.J., Fusco F., Gravas S., Oelke M., Peyronnet B., Tutolo M., van Koeveringe G., Madersbacher S. | en |
| dc.date.accessioned | 2023-01-31T07:52:11Z | |
| dc.date.available | 2023-01-31T07:52:11Z | |
| dc.date.issued | 2021 | |
| dc.identifier | 10.1016/j.eururo.2021.02.033 | |
| dc.identifier.issn | 03022838 | |
| dc.identifier.uri | http://hdl.handle.net/11615/73145 | |
| dc.description.abstract | [No abstract available] | en |
| dc.language.iso | en | en |
| dc.source | European Urology | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103929870&doi=10.1016%2fj.eururo.2021.02.033&partnerID=40&md5=4e78394ddc512692246251af0a334d0d | |
| dc.subject | muscarinic receptor blocking agent | en |
| dc.subject | muscarinic receptor blocking agent | en |
| dc.subject | human | en |
| dc.subject | information retrieval | en |
| dc.subject | Letter | en |
| dc.subject | male | en |
| dc.subject | methodology | en |
| dc.subject | overactive bladder | en |
| dc.subject | pharmaceutical care | en |
| dc.subject | practice guideline | en |
| dc.subject | Preferred Reporting Items for Systematic Reviews and Meta-Analyses | en |
| dc.subject | priority journal | en |
| dc.subject | prospero protocol | en |
| dc.subject | publication bias | en |
| dc.subject | publishing | en |
| dc.subject | quality assessment tool | en |
| dc.subject | randomized controlled trial (topic) | en |
| dc.subject | systematic review (topic) | en |
| dc.subject | therapy | en |
| dc.subject | unmet medical need | en |
| dc.subject | overactive bladder | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Muscarinic Antagonists | en |
| dc.subject | Urinary Bladder, Overactive | en |
| dc.subject | Elsevier B.V. | en |
| dc.title | Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschleipfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492–504 | en |
| dc.type | other | en |